###begin article-title 0
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
Role of APC and DNA mismatch repair genes in the development of colorectal cancers
###end article-title 0
###begin p 1
###xml 609 612 609 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 81 84 <span type="species:ncbi:9606">men</span>
###xml 89 94 <span type="species:ncbi:9606">women</span>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
Colorectal cancer is the third most common cause of cancer-related death in both men and women in the western hemisphere. According to the American Cancer Society, an estimated 105,500 new cases of colon cancer with 57,100 deaths will occur in the U.S. in 2003, accounting for about 10% of cancer deaths. Among the colon cancer patients, hereditary risk contributes approximately 20%. The main inherited colorectal cancers are the familial adenomatous polyposis (FAP) and the hereditary nonpolyposis colorectal cancers (HNPCC). The FAP and HNPCC are caused due to mutations in the adenomatous polyposis coli (APC) and DNA mismatch repair (MMR) genes. The focus of this review is to summarize the functions of APC and MMR gene products in the development of colorectal cancers.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 245 246 245 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 830 831 830 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 991 992 991 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 952 960 <span type="species:ncbi:9606">patients</span>
Prognosis of colorectal cancer depends on the stage of the tumor at the time of diagnosis, with surgery being the most effective treatment. Colorectal cancers develop through a series of histological distinct stages from "adenoma to carcinoma" [1]. Recently, the multi-step model of colon cancer development by Fearon and Vogelstein [2] is revised and presented in greater detail to include the interdependence of different pathways and involvement of many more gene mutations than before [3,4]. Genes which are mutated at different stages of colorectal cancer development include tumor suppressor genes, proto-oncogenes, DNA repair genes, growth factors and their receptor genes, cell cycle checkpoint genes, and apoptosis-related genes (Fig. 1). In contrast to the predictions of sequential mutation accumulation of genes (Fig. 1), a recent study presented a quite different view in which the gene mutation spectrum in a large cohort of colon cancer patients was correlative to only 6.6% [5]. The heterogeneous pattern of tumor mutations found in this study suggests that multiple alternative genetic pathways to colorectal cancer exist and that the widely accepted genetic model of cancer development is not representative of the majority of colorectal tumors. However, it is believed that mutations in one of these genes set the stage for initiation and transformation of the normal colonic epithelial cells. Further accumulation of mutations in other genes then contributes to the progression of cancer through adenoma - carcinoma - metastasis stages. During accumulation of genetic changes, a complex signaling network is established among inactivated and activated cellular pathways. Many cells bearing defective signaling pathways may go through programmed cell death or apoptosis and may be removed from the normal population of cells; however, one of the target cells can go through the selection process and survive among other cells by overruling cell cycle checkpoints and abrogating apoptosis pathways. After clonal expansion, the genetically modified single cell can become a full grown tumor.
###end p 3
###begin p 4
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Model for genetic alterations in the development of colorectal cancer. </bold>
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 355 358 355 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 390 393 390 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCC</italic>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 585 650 585 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH3, hMSH6, TGF&#946;IIR, IGFIIR, PTEN, BLM, Tcf-4, Bax and E2F4 </italic>
###xml 909 955 906 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p15, p16, Bub1, cyclin D1, tPa, CEA, Nm23, MMP</italic>
###xml 969 973 966 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 976 980 973 977 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD44</italic>
###xml 1113 1124 1110 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 1399 1400 1388 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1113 1123 <span type="species:ncbi:7227">Drosophila</span>
Model for genetic alterations in the development of colorectal cancer. Based on genetic analysis, at least two pathways are characterized in detail, which lead to colon cancer development. One pathway (indicated with red arrows) initiates with mutations in the adenomatous polyposis (APC) gene and chromosomal instability (CIN) followed by mutations in K-ras, deleted in colorectal cancer (DCC) and p53 genes. The second pathway (indicated with blue arrows) is initiated by the mutations in the mismatch repair (MMR) genes and microsatellite instability (MSI) followed by mutations in hMSH3, hMSH6, TGFbetaIIR, IGFIIR, PTEN, BLM, Tcf-4, Bax and E2F4 genes. Other pathways are less characterized, but a high degree of overlapping is expected among them. At least, seven gene mutations are needed to develop a normal epithelial cell into carcinoma. However, a cluster of gene and chromosome aberrations such as p15, p16, Bub1, cyclin D1, tPa, CEA, Nm23, MMP, E-cadherin (CDH1), CD44, 7q, 14q, 22q and 8p are observed in carcinoma and metastatic tumors. ASEF, APC-stimulated guanine nucleotide exchange factor; DLG, Drosophila discs large; EB1, end-binding protein 1, KAP3A, kinesin superfamily-associated protein 3A; MCR, mutator cluster region; NES, nuclear export signal; NLS, nuclear localization signal; PP2-B56alpha, protein phosphates 2A B56alpha subunit. This figure is adapted from reference [7].
###end p 4
###begin p 5
###xml 347 350 347 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink">STKII</italic>
###xml 783 793 783 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad4/DPC4</italic>
###xml 863 867 863 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
Many colon cancer syndromes have been characterized based upon their phenotypic, histological and genetic changes. Among them, the most common and highly studied colon cancer syndromes are familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancers (HNPCC), which are caused by mutations in the adenomatous polyposis coli (APC) and mismatch repair (MMR) genes, respectively. Other colon cancer syndromes include Peutz-Jeghers syndrome (PJS), Juvenile polyposis syndrome (JPS), hereditary mixed polyposis syndrome (MHAP) and Cowden's syndrome. These syndromes contain hamartomatous polyps and are inherited in an autosomal dominant fashion. Mutations in serine-threonine kinase II (STKII) gene, Sma and Mad-related protein 4/Deleted in pancreatic carcinoma 4 (Smad4/DPC4) gene, and phsophatase and tensin homolog deleted on chromosome ten (PTEN) gene are linked with PJS, JPS and Cowden's syndromes, respectively. The inherited syndromes account for only 3-5% of all colon cancers, and the rest are the somatic colon cancers in which both alleles of the tumor suppressor genes are inactivated somatically
###end p 5
###begin title 6
###xml 28 31 28 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
Adenomatous polyposis coli (APC) gene mutations are the earliest events in the multi-step colorectal cancer development
###end title 6
###begin p 7
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 193 197 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 815 819 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 895 896 895 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 903 907 903 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1007 1008 1007 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1061 1065 1061 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1110 1114 1110 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1196 1198 1196 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1270 1274 1270 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1318 1322 1318 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1385 1387 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1426 1430 1426 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1627 1628 1627 1628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1679 1683 1679 1683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">via </italic>
###xml 1714 1716 1714 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1742 1743 1742 1743 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1881 1883 1881 1883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1884 1886 1884 1886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1939 1941 1939 1941 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2161 2163 2161 2163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 2014 2019 <span type="species:ncbi:10090">mouse</span>
###xml 2084 2089 <span type="species:ncbi:10090">mouse</span>
###xml 2138 2143 <span type="species:ncbi:9606">human</span>
Mutations in the APC gene on chromosome 5q21 locus are considered as one of the earliest events in the initiation and progression of colorectal cancer. In FAP patients, allelic mutation of the APC gene followed by a loss of heterozygosity (LOH) is a common feature. Notably, mutations in the APC gene also are found in 60 to 80% of sporadic colorectal cancers and adenomas. FAP patients with APC mutations are prone to hundreds to thousands of colorectal adenomas and early onset carcinoma. FAP patients also are prone to small intestinal adenomas (and carcinomas), intra-abdominal desmoids and osteomas tumors (Gardner's syndrome), congenital hypertrophy of retinal pigment epithelium (CHRPE), fundic gland polyps in the stomach, pancreas and thyroid, dental abnormalities, and epidermal cysts [6,7]. Mutations in APC are also associated with malignant brain tumors known as Turcot's syndrome [8]. The APC locus on chromosome 5q21 shows loss of heterozygosity (LOH) in approximately 25% of breast cancers [9]. Approximately 18% of somatic breast cancers carry APC gene mutations [10]. Furthermore, LOH at the APC gene locus is frequently seen in the early stages of non-small cell lung cancers [11]. In an animal model for carcinogen-induced lung tumors, a decrease in APC gene expression, rather than an increase in APC mutations, has been shown to be associated with tumorigenesis [12]. The diverse effects of mutations in APC gene indicates that this molecule plays a key role in the regulation of cell growth in a number of colonic and extra-colonic tissues. It has been suggested that the overexpression of APC causes a G1/S phase checkpoint in serum-treated NIH-3T3 cells via components of the pRB pathway [13]. A role for APC in the G2/M phase transition is also expected, given that APC is hyperphosphorylated during M-phase and is a target of the M-phase kinase p34Cdc2 [14,15]. In a recent study, a direct role of APC in S and G2 phase arrest of cell cycle has been described in cell lines immortalized mouse epidermal keratinocytes, immortalized canine kidney epithelial, mouse squamous cell carcinoma and skin papilloma, and human colon carcimona [16].
###end p 7
###begin p 8
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 198 202 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 532 533 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 564 567 564 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 567 570 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 567 573 567 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+ </sup>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 813 817 813 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 925 926 925 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1318 1319 1315 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1360 1364 1357 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1533 1535 1530 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1536 1538 1533 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1636 1638 1633 1635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1808 1812 1805 1809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1867 1869 1864 1866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 783 787 <span type="species:ncbi:10090">mice</span>
###xml 1641 1649 <span type="species:ncbi:9606">Patients</span>
APC is expressed constitutively within the normal colonic epithelium. The APC gene product is a 310 kDa protein localized in both the cytoplasm and the nucleus. Recently, it has been shown that the APC gene is inducible, which is transcriptionally up-regulated by p53 in response to DNA damage [17-19]. p53 is a negative regulator of normal cell growth and division. Although mutations in the p53 gene is also widely present in colorectal cancers, its consequence on the expression of the wild-type or mutant APC gene is not clear [2]. In an earlier study, in the ApcMin/+ (Min, multiple intestinal neoplasia) mice model, an increased multiplicity and invasiveness of intestinal adenomas was associated with deficiency for p53 [20]. Also, the occurrence of desmoid fibromas in these mice was strongly enhanced by p53 deficiency. The structure of the APC protein with different protein interaction domains are given in Figure 2. At the N-terminal site, the APC protein contains oligomerization and Armadillo-repeat binding domains; and at the C-terminal site there are EB1 and tumor suppressor protein DLG binding domains. The APC protein also contains three 15-amino acids and seven 20-amino acids repeat regions in which the latter is involved in the negative regulation of beta-catenin protein levels in cells (Fig. 2). The first 20-amino acid-repeat in the APC gene is located at the 5'-end of the mutation cluster region (MCR). An association has been shown between severe polyposis phenotype and germ-line mutations in the MCR [21-24]. Selective pressure for an MCR mutant has been proposed based on the germ-line mutation in FAP [25]. Patients with mutations outside of the MCR region have a milder phenotype. A recent study has shown that animals with homozygous truncating mutations at codon 1638 of APC did not develop tumors and survived through adulthood [26].
###end p 8
###begin p 9
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Structural features of the APC protein. </bold>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
Structural features of the APC protein. Most of the mutations in APC occur in the mutator cluster region (MCR) and create truncated proteins. The truncated proteins contain ASEF and beta-catenin binding sites in the armadillo-repeat domain but looses the beta-catenin regulatory activity which is located in the 20-amino acids repeat domain. Somatic mutations are selected more frequently in FAP patients with germ-line mutations outside of the MCR.
###end p 9
###begin p 10
###xml 125 127 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 128 130 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 357 359 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 360 362 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 438 440 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 441 443 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 444 446 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 724 726 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 727 729 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
It has been reported recently that APC functions as a nuclear-cytoplasmic shuttling protein and as a beta-catenin chaperone [27-31]. There are at least five APC nuclear export signals (NESs). Among them, two are Rev-type NESs located at the N-terminal region and the other three are located in the 20-amino acid repeat region of beta-catenin binding motif [29,32]. The nuclear export of APC is mediated by CRM1/Exportin receptor pathway [28-30,33]. The APC protein has two nuclear localization signals, NLS1 (1767-1772; amino acids GKKKKP) and NLS2 (2048-2053; amino acids PKKKKP). The nuclear localization of APC is controlled by post-translational modification of NLS residues by protein kinase 2 and/or protein kinase A [32-34].
###end p 10
###begin title 11
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
APC regulates beta-catenin levels through Wnt-signaling
###end title 11
###begin p 12
###xml 141 143 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 144 146 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 218 228 215 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 230 237 227 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus</italic>
###xml 386 388 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 389 391 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 428 429 425 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 853 855 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 856 858 832 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 965 967 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 968 970 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1069 1071 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1072 1074 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1248 1250 1206 1208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1251 1253 1209 1211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1498 1503 1453 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tcf4 </italic>
###xml 1558 1560 1513 1515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1647 1653 1599 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 1654 1656 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1664 1665 1616 1617 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1679 1689 1631 1641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1 </italic>
###xml 1690 1692 1642 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1753 1762 1705 1714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">matrysin </italic>
###xml 1763 1765 1715 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1799 1805 1751 1757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-jun </italic>
###xml 1809 1814 1761 1766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">fra-1</italic>
###xml 1876 1878 1828 1830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 218 228 <span type="species:ncbi:7227">Drosophila</span>
###xml 230 237 <span type="species:ncbi:8355">Xenopus</span>
###xml 1492 1497 <span type="species:ncbi:9606">human</span>
APC may act as a negative regulator of beta-catenin signaling in the transformation of colonic epithelial cells and in melanoma progression [35-37]. The role of the Wingless/Wnt signaling pathway has been described in Drosophila, Xenopus, and in vertebrates. This pathway is important in organ development, cellular proliferation, morphology, motility, and the fate of embryonic cells [38-40]. In a simple model shown in Figure 3, Wingless/Wnt signaling regulates the assembly of a complex consisting of: axin (and its homologs Axinl and conductin), APC, beta-catenin, and glycogen synthase-3beta kinase (GSK3beta). Axin (Axil/conductin) binds to form a complex with APC, beta-catenin, and GSK3beta to promote beta-catenin phosphorylation and subsequent binding with slim (beta-TrCP) which mediates its ubiquitination and degradation in the proteasome [41,42]. GSK3beta regulates this process by phosphorylating beta-catenin, APC and Axin (Axil/conductin) complex [43-45]. Activation of the Wingless/Wnt signaling pathway inhibits GSK3beta and stabilizes beta-catenin [46,47]. Mutations of beta-catenin or truncation of APC, which occur both in colon cancer and melanoma cells, increases the stability and transcriptional activity of beta-catenin [37,48]. The stabilized pool of beta-catenin associates with members of the T-cell factor (Tcf)-lymphoid enhancer factor (Lef) family of transcription factors. There are four known members of the Tcf and Lef family in mammals, one of which, the human Tcf4 gene, is expressed specifically in colon cancer cells [35]. The beta-catenin/Tcf4 complex regulates the proto-oncogene and cell cycle regulator c-myc [48], the G1/S-regulating cyclin D1 [49], the gene encoding the matrix-degrading metalloproteinase, matrysin [50], the AP-1 transcription factors c-jun and fra-1; and the urokinase-type plasminogen activator receptor gene [51]. From this discussion, it is clear that the inactivation of APC causes activation of beta-catenin, which results in the constitutive activation of Tcf/Lef response genes.
###end p 12
###begin p 13
###xml 0 39 0 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A model for the Wnt-signaling pathway. </bold>
###xml 39 47 39 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel A </bold>
###xml 1041 1047 1011 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 1050 1060 1020 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1 </italic>
###xml 1203 1311 1170 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cyclin D1, CDH1, Tcf-1, c-jun, Fra-1, PPARd, Gastrin, uPAR, MMP7, Conductin, CD44, Id2, Siamois, Xbra, Twin </italic>
###xml 1315 1318 1282 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ubx</italic>
###xml 1320 1328 1287 1295 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel B </bold>
A model for the Wnt-signaling pathway. Panel A depicts the down-regulation of beta-catenin transactivation activity in normal colonic epithelial cells. beta-catenin remains in a complex of Axin/Axil/conductin, APC, GSK3beta kinase and casein kinase 1 or 2 (CK1 or 2). In the absence of Wnt-signaling, GSK3beta and CK1 or 2 kinases become active and phosphorylate beta-catenin at serine and threonine residues in the N-terminal domain. Axin and APC promote phosphorylation of beta-catenin by acting as a scaffoled protein and bringing together enzyme(s) and substrate(s). The phosphorylated beta-catenin then binds with F-box protein beta-TrCP of the Skp1-Cullin-F-box (SCF) complex of ubiquitin ligases and undergoes proteasomal degradation. Even though Tcf-Lef transcription factor without beta-catenin may bind to DNA in the absence of beta-catenin, the repressors and corepressors such as CtBP (carboxy-terminal binding protein), CBP (CREB-binding protein), Gro (Groucho), LRP (LDL-receptor-related protein) bind with Tcf-Lef and repress c-myc or cyclin D1 gene expression to control cell cycle progression. Some other known genes which are regulated by beta-catenin/Tcf-Lef pathway are given here - cyclin D1, CDH1, Tcf-1, c-jun, Fra-1, PPARd, Gastrin, uPAR, MMP7, Conductin, CD44, Id2, Siamois, Xbra, Twin and Ubx. Panel B shows the role of mutations in the APC or beta-catenin protein in the regulation of beta-catenin level and its transactivation property in colon cancer cells. The mutant beta-catenin escapes its degradation through Wnt-pathway and becomes stabilized in the cytoplasm. The stabilized level of beta-catenin then heterodimerizes with Tcf-Lef transcription factor and locates into the nucleus, where it actively transcribes cell cycle related genes causing cellular proliferation. The binding of beta-catenin with Tcf-Lef inhibits the binding of CtBP, CBP, Gro or LRP and potentiates its transcriptional activity.
###end p 13
###begin p 14
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 272 278 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 421 426 418 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4 </italic>
###xml 491 493 488 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 500 502 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 509 515 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 683 688 680 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdk4 </italic>
###xml 1059 1061 1056 1058 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1333 1335 1330 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 1380 1384 1377 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1427 1433 1421 1427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-myc </italic>
###xml 1300 1305 <span type="species:ncbi:10090">mouse</span>
In many cases, it has been observed that colon tumors carrying mutations in the APC gene also carried increased levels of c-Myc, a known factor for cellular proliferation. Recently, a direct link has been established between APC gene mutation, beta-catenin activation and c-myc gene up-regulation in colon cancer development. The increased expression of c-Myc through Wnt-signaling pathway up-regulates the expression of Cdk4 gene, whose product is responsible for cell cycle regulation in G1 phase [52]. The c-myc gene encodes a transcription factor of helix-loop-helix leucine zipper family that binds as a heterodimer with Max to E boxes (CACGTG) on target promoters, for example Cdk4 gene, and activates its expression. Max can also interact with Mad and Mxi1 and down-regulate c-Myc target gene expression. It has been suggested that the increased levels of Cdk4 protein can phosphorylate pRB. The E2F/DP transcription factor then dissociates from the hyperphosphorylated pRB, which actively transcribes genes involved in cell cycle progression through G1 phase. It is also suggested that the increased levels of Cdk4 may sequester cell cycle kinase inhibitor p21, p27, and p16. This sequestration may account for the ability of c-Myc overexpression to substitute for p16 deficiency as noted in mouse fibroblast transformation [53]. These studies thus establish a link among APC gene mutation, beta-catenin stabilization, c-myc gene activation, and Cdk4/cyclin D1/pRB/p16 pathway in colorectal cancer development.
###end p 14
###begin title 15
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
APC is involved in actin cytoskeletal integrity, cell-cell adhesion and cell migration
###end title 15
###begin p 16
###xml 408 410 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 416 426 406 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 509 511 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 512 514 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 770 772 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 907 909 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 416 426 <span type="species:ncbi:7227">Drosophila</span>
###xml 665 668 <span type="species:ncbi:10116">rat</span>
Actin cytoskeletal integrity is necessary to maintain the shape and adherence junctions of cells. The imbalance in actin cytoskeletal integrity can cause disturbance in cell-cell adhesion and cell migration. The role of APC in actin cytoskeletal maintenance is predicted through its interaction with beta-catenin. beta-catenin establishes a link between APC and actin by providing a bridge to alpha-catenin [53]. In Drosophila, mutations in E-APC have shown to affect the organization of adherence junctions [54-56]. Another link of APC with actin is shown through its interaction with PDZ domain of DLG protein. Since APC co-localizes with DLG in the cytoplasm in rat colon epithelial cells, the APC-DLG complex may participate in regulation of cell cycle progression [57]. Mutant APC lacking the S/TXV motif for DLG binding exhibits weaker cell cycle blocking activity at Go/G1 phase than the intact APC [58].
###end p 16
###begin p 17
###xml 170 172 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 173 175 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 197 198 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 421 423 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 581 583 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 584 586 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 822 824 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 972 974 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1259 1263 1226 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1277 1279 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 1415 1417 1382 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 1418 1420 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
Interaction of APC with beta-catenin and through beta-catenin interaction with the members of the cadherin family of proteins have been implicated in cell-cell adhesion [24,59]. As shown in Figure 4, the C-terminal domain of E-cadherin interacts with beta- and gamma-catenin, which associate with alpha-catenin and form an E-cadherin complex with actin cytoskeleton. This complex maintains the stable cell-cell adhesion [59]. APC becomes a part of the cell-cell adhesion complex linked with E-cadherin, since it directly binds with beta-catenin, gamma-catenin, and actin filament [24,60]. The tyrosine phosphorylation of beta-catenin by epidermal growth factor (EGF), hepatocyte growth factor (HGF) and c-Met receptors is important in modulating cadherin-catenin complexes from membrane bound form to free cytosolic form [61]. The phosphorylation of beta-catenin at tyrosine residue, which is blocked by tyrosine phosphatase Pez, is involved in epithelial cell migration [62]. If the Wnt-pathway and the EGFR or c-Met receptors pathway are activated at the same time, then the degradation of beta-catenin can be inhibited and it may translocate to the nucleus, bind to the Lef-Tcf transcription factor, and down-regulate the transcription of E-cadherin gene, CDH1, expression [63]. These complex interactions may finally result in the reduction in E-cadherin-mediated cell-cell adhesion and proliferation of cells [64-66].
###end p 17
###begin p 18
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 0 131 0 131 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mutations in <italic>APC </italic>gene impair actin cytoskeletal integrity, cell-cell adhesion and cell migration properties of colon cancer cells. </bold>
###xml 131 139 131 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel A </bold>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 549 557 549 557 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel B </bold>
###xml 584 588 584 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 725 729 725 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
Mutations in APC gene impair actin cytoskeletal integrity, cell-cell adhesion and cell migration properties of colon cancer cells. Panel A shows the organization of cell-cell adhesion and cytoskeletal proteins in normal colonic epithelial cells. The APC gene product is shown to bind through its armadillo repeat domain to ASEF. Endogenous APC co-localizes with ASEF in colonic epithelial cells. APC regulates guanine nucleotide exchange factor (GEF) activity of ASEF and maintains actin cytoskeletal network, cell-cell adhesion and cell migration. Panel B shows how mutations in the APC gene product may impair actin cytoskeletal network, cell-cell adhesion and cell migration properties of colon cancer cells. Mutations in APC gene product disrupt binding with actin and beta-catenin; thus it affects actin cytoskeletal network and cell-cell adhesion, respectively. ASEF binds with most APC mutant proteins containing armadillo repeat sites, stimulates its own GEF activity, and promotes cell migration.
###end p 18
###begin p 19
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 1352 1354 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 1355 1357 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 1690 1692 1675 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 1693 1695 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
Another important role for APC is assigned in cell migration. Colonic epithelial cells, derived from a committed stem cell, divide in the lower two-third of the crypts and migrate rapidly to the surface to form a single layer. During migration, they are differentiated into absorptive, secretory, paneth and endocrine cells. The function of a wild-type APC is necessary in maintaining the direction of upward movement of these cells along the crypt-villus axis. Loss of wild-type APC functions due to loss of expression or mutations affect cell migration. These cells, instead of migrating upwards towards the gut lumen, migrate aberrantly or less efficiently towards the crypt base where they accumulate and form polyps [67]. In due time, these cells become aneuploid due to defects in chromosome segregation as well as acquiring beta-catenin stabilization and activation of genes for cell proliferation. The mechanisms by which APC might be involved in cell migration can be understood by its association with the kinesin superfamily-associated protein KAP3 that has been established in cell-cell adhesion and migration. It has been shown that APC, mediated by KAP3, interacts with kinesin motor proteins which transport it as well as beta-catenin along the microtubules to the growing ends of the cytoskeletal protruding into motile cell membranes [68,69]. At the tip of the microtubule, APC interacts with the end-binding protein EB1 and protein tyrosine phosphatase PTP-BL. PTP-BL modulates the steady state levels of tyrosine phosphorylations of APC associated proteins such as beta-catenin and GSK3beta. In fact, GSK3beta kinase activity has been implicated in microtubule dynamics [70,71].
###end p 19
###begin p 20
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
Recently, experimental evidence was presented describing the mechanisms by which the mutated APC might play a role in the migration of colorectal tumor cells [72,73]. In these studies, an interaction of APC has been shown with APC-stimulated guanine nucleotide exchange factor (ASEF) that may regulate the actin cytoskeletal network [72]. APC binds with ASEF and controls its activity. ASEF is activated in colorectal cancer cells containing truncated APC. Active ASEF decreases E-cadherin-mediated cell-cell adhesion and promotes cell migration. Thus, the dynamic association of APC, EB1, ASEF, catenins, EGFR or c-Met receptor, PTP-BL and E-cadherin proteins at cell-cell adherence junctions and microtubule ends play an important role in cell-cell communication, cell migration and carcinogenesis.
###end p 20
###begin title 21
Genetic instability in colon cancer progression
###end title 21
###begin p 22
Both sporadic and hereditary colorectal cancers exhibit a defined set of biological and genetic cell heterogeneity through a series of molecular events. Two specific pathologically distinct genetic pathways for colorectal cancer have been identified - the chromosomal instability (CIN) pathway and the microsatellite instability (MSI) pathway. The CIN and MSI are associated with two major inherited syndromes, familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), respectively. The MSI leads to a 1,000-fold increase in the rate of subtle DNA changes, whereas CIN enhances the rate at which gross chromosomal changes occur during cell division such as chromosome breaks, duplication, rearrangements, and deletions. The latest findings describing these two pathways are discussed below.
###end p 22
###begin title 23
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
Mutations in APC gene is associated with chromosomal instability (CIN)
###end title 23
###begin p 24
###xml 777 781 777 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 1269 1271 1269 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 1397 1399 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 1411 1415 1411 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1649 1651 1649 1651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
Aneuploidy, the abnormal number of chromosomes both quantitatively and qualitatively, is proposed to be a common characteristic of colon cancer cells. It is believed that the aneuploidy in colon cancer cells arises during mitosis through a defective cell division leading to CIN. CIN is a common feature of about 85% colorectal cancers, and it has been detected in the smallest adenoma, suggesting that CIN may occur at very early stages of colorectal cancer development. The mechanism(s) by which CIN is generated in colon cancer cells is largely unclear. Since the main feature of CIN is aneuploidy, it has been predicted that it may arise due to structural changes to the chromosomes and abnormal mitosis. In the year 2001, two different research groups linked mutations in APC gene with CIN [74,75]. Their results suggested that the wild-type APC may be involved in maintaining the proper connection of microtubules with chromosomes. APC performs a bridging function between microtubules and chromosomes. APC binds at the plus end of the microtubule through EB1, stretches it to the chromosomes, and inserts them into kinetochores after binding with Bub1. APC co-localizes to kinetochores and form complexes with Bub1 and Bub3, the two mitotic checkpoint proteins [75]. The successful complex formation may facilitate proper growth of spindle formation and helps in maintaining euploidy (Fig. 5A). Once the APC gene is mutated, the truncated APC protein may loose its ability to bind with Bub1, and it may become unable to properly maintain the attachment of microtubules at kinetochores, resulting in defect in segregation of chromosomes (Fig. 5B).
###end p 24
###begin p 25
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Chromosomal instability (CIN) in cells carrying mutations in <italic>APC </italic>gene. </bold>
###xml 71 79 71 79 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel A </bold>
###xml 318 326 318 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel B </bold>
Chromosomal instability (CIN) in cells carrying mutations in APC gene. Panel A shows a model for the interaction of APC with plus-end of microtubule through EB1 and with kinetochore of chromosome through Bub1 in normal colonic epithelial cells. APC can also bind microtubules directly via the C-terminal basic domain. Panel B shows a disruption in the interaction between spindle microtubules and kinetochores due to expression of truncated form of APC in colon cancer cells.
###end p 25
###begin p 26
###xml 142 145 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 145 148 145 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 145 151 145 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+ </sup>
###xml 154 163 154 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc1638T </italic>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 976 979 976 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 979 982 979 982 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 979 985 979 985 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+ </sup>
###xml 989 993 989 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1107 1109 1107 1109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 993 998 <span type="species:ncbi:10090">mouse</span>
###xml 1221 1226 <span type="species:ncbi:9606">human</span>
These studies also pointed out another interesting observation associated with CIN. It has been found that after blocking apoptosis in either ApcMin/+ or Apc1638T ES cells, the number of aberrant chromosomes were much greater than in control ES cells that were unable to undergo apoptosis [74]. From these results, a multiple-hit hypothesis of colorectal cancer development has been suggested. The chromosome segregation defect in colon cancer cells with mutated APC gene could lie dormant until an additional genetic-hit suppresses the mitotic checkpoint or the apoptosis of defective cells. In this regard, the proper functioning of the hSecurin, a protein which is necessary for the completion of the anaphase portion of mitosis, is critical to maintain euploidy, since the loss of hSecurin is often associated with the loss of chromosomes at a high frequency [76]. Furthermore, telomere dysfunction has been shown to promote CIN that triggered early carcinogenesis in the ApcMin/+ Terc-/- mouse models, while telomerase activation restored genomic stability to a level permissive for tumor progression [77]. These studies suggested that early and transient telomere dysfunction is a major mechanism underlying CIN of human cancer. Thus, multiple factors may play together in colorectal cancer development from normal epithelial cells - adenoma - carcinoma stages.
###end p 26
###begin title 27
Mutations in mismatch repair (MMR) genes are associated with microsatellite instability (MSI)
###end title 27
###begin p 28
###xml 589 591 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 879 881 879 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 1369 1375 1369 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH2 </italic>
###xml 1379 1385 1379 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 1462 1464 1462 1464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 1838 1840 1831 1833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 2227 2229 2213 2215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 2288 2294 2274 2280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 2424 2430 2410 2416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 2523 2525 2509 2511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 2526 2528 2512 2514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 2770 2776 2756 2762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 2813 2819 2799 2805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1 </italic>
###xml 2866 2868 2852 2854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 3330 3340 3313 3320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII</italic>
###xml 3343 3355 3323 3335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH3, hMSH6</italic>
###xml 3397 3403 3377 3383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFIIR</italic>
###xml 3472 3476 3452 3456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 3497 3500 3477 3480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLM</italic>
###xml 3538 3543 3518 3523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tcf-4</italic>
###xml 3571 3575 3551 3555 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F4</italic>
###xml 3600 3604 3580 3584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax </italic>
###xml 3605 3607 3585 3587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 3608 3610 3588 3590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
###xml 799 805 <span type="species:ncbi:9606">humans</span>
###xml 1452 1460 <span type="species:ncbi:9606">patients</span>
###xml 2217 2225 <span type="species:ncbi:9606">patients</span>
Microsatellite instability (MSI) is characterized by the size variation of microsatellites in tumor DNA as compared to matching normal DNA due to defects in the mismatch repair (MMR) system. MMR system is critical for the maintenance of genomic stability. MMR increases the fidelity of DNA replication by identifying and excising single-base mismatches and insertion-deletion loops that may arise during DNA replication. Thus, the MMR system serves a DNA damage surveillance function by preventing incorrect base pairing or avoiding insertion-deletion loops by slippage of DNA polymerase [78]. Once cells compromise with these functions, then it may lead to accumulation of mutations resulting in the initiation of cancer. The MMR genes are involved in one of the most prevalent cancer syndromes in humans known as hereditary nonpolyposis colon cancer (HNPCC) or Lynch syndrome [79]. HNPCC is characterized as an autosomal dominant inherited disease with 85-90% gene penetrance for early-onset of colorectal carcinoma. HNPCC accounts for about 5-7% of cases of colorectal carcinoma. The molecular diagnosis of HNPCC is based on determining MMR genes for germ-line mutations. There are at least six different proteins required for the complete MMR system. These proteins are hMSH2, hMLH1, hPMS1, hPMS2, hMSH3 and hMSH6 (GTBP). Recently, mutational germ-line analysis of hMSH2 and hMLH1 genes has been suggested to cause early onset in colorectal cancer patients [80]. hMSH2 forms a heterodimer with either hMSH6 or hMSH3 (depending on the type of lesion to be repaired) and binds to the mismatch site. The complex of hMSH2 with hMSH6 is called hMutSalpha, and it is required for the correction of single-base mispairs. The complex of hMSH2 with hMSH3 is called hMutSbeta, and it is required for the correction of insertion-deletion loops [81]. Subsequently, a heterodimer of hMLH1 and hPMS2 proteins are recruited by hMutSalpha or hMutSbeta proteins to the mismatch recognition complex, which along with other proteins are involved in excision, resynthesis and ligation of DNA. Mutations in the hMLH1 and hPMS2 have been found in about 90% of HNPCC cases. Mutations in other MMR genes have been less frequent in HNPCC patients [79]. In many sporadic colon cancers, hypermethylation of the hMLH1 gene promoter resulting in its transcriptional silencing has been observed more than mutations. Both mutations and methylation of hMLH1 gene have been linked with MSI playing a causal role in the initiation of colorectal cancer [82-84]. Recently, the CpG island methylator phenotype (CIMP) pathway has been suggested as a novel mutator pathway that predisposes to colonic tumorigenesis. In many cases of the sporadic colon cancers, the MSI can be induced by CIMP, followed by hMLH1 gene's promoter methylation, loss of hMLH1 gene expression, and resultant MMR deficiency [85]. Mutation rate in cells with MMR deficiency are 100-1,000-fold greater than in normal cells. There are many targets of MMR gene inactivation; however, the precise stage of tumorigenesis in which mutation of the wild-type MMR gene occurs is not clear. There are few well studied gene targets of MMR, whose mutations in the microsatellite region have been found in gastrointestinal tumors. These gene targets are the transforming growth factor-beta receptor II (TGFbetaRII), hMSH3, hMSH6, insulin like growth factor II receptor (IGFIIR), phosphatase and tension homologue deleted on chromosome ten gene (PTEN), caspase 5, Bloom (BLM) syndrome helicase, T-cell factor 4 (Tcf-4), the cell cycle regulator E2F4, and antiapoptotic gene Bax [86-95].
###end p 28
###begin title 29
Altered TGFbeta signaling in MSI cells
###end title 29
###begin p 30
###xml 405 407 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 488 499 470 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 515 517 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
###xml 707 718 686 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 837 848 813 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 866 868 839 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 929 931 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 932 934 905 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
###xml 935 937 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B97">97</xref>
###xml 1084 1095 1057 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 1245 1246 1209 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1313 1318 1277 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAI-1</italic>
###xml 1358 1362 1322 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p15 </italic>
###xml 1529 1531 1490 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B98">98</xref>
###xml 1585 1586 1543 1544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1650 1654 1608 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p15 </italic>
###xml 1655 1657 1613 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B99">99</xref>
###xml 1809 1812 1761 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 1812 1815 1764 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 1812 1818 1764 1770 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+ </sup>
###xml 1850 1856 1802 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Smad4 </italic>
###xml 1860 1864 1812 1816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1970 1974 1922 1926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1991 1994 1943 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B100">100</xref>
###xml 2091 2098 2043 2050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGFIIR </italic>
###xml 413 418 <span type="species:ncbi:9606">human</span>
###xml 1803 1808 <span type="species:ncbi:10090">mouse</span>
###xml 1818 1823 <span type="species:ncbi:10090">mouse</span>
###xml 2026 2031 <span type="species:ncbi:9606">human</span>
In colon cancers, transforming growth factor-beta (TGFbeta) signaling potently inhibits the growth of normal epithelial cells, since the tumor cells are frequently resistant to TGFbeta; they cause pre-neoplastic lesions, increase motility and spread cancer. The structural basis for TGFbeta resistance in colon cancers is defined due to somatic mutations that inactivate TGFbeta receptor II (TGFbetaRII) [86]. In human colon cancer cell lines with high rates of MSI, the mutations in the TGFbetaRII gene was found [96]. These are primarily frameshift mutations that add or delete one or two adenine bases within or from 10 base-pair poly(A) repeat in the cysteine-rich coding region (codons 125-128) of the TGFbetaRII gene. Mutations in this region consist of 1- or 2-base deletions or insertions. The other microsatellite region in the TGFbetaRII gene is a poly(GT)3 that was found with insertion of an extra GT in this region [86,96,97]. These mutations produce truncated proteins that lack the cytoplasmic domain. As much as 90% of the colorectal cancers with MSI have the mutated TGFbetaRII gene. TGFbetaIIR responses are connected with Smads, tumor suppressor gene products, which help to initiate TGFbeta-mediated gene transcription (Fig. 6). The transcriptional regulation of Type 1 plasminogen inhibitor (PAI-1) and cyclin dependent kinase inhibitor p15 genes are controlled by TGFbeta signaling. PAI-1 is the primary inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type 1 plasminogen activator (uPA) [98]. TGFbeta inhibits cell proliferation by inducing a G1-phase cell cycle arrest acting through increased expression of p15 [99]. Thus, the loss of TGFbetaIIR or Smad4 can abolish TGFbeta-signaling and advocate cell proliferation and development of colorectal cancer. In a mouse ApcMin/+ mouse model, the combination of Smad4 and APC gene mutations have been shown to cause rapid tumor formation of the benign lesions arising only from the APC gene deficiency [100]. These studies, reiterate the human data that put forward the hypothesis that mutations in the TGFIIR gene contribute to adenoma - carcinoma stage progression in colon.
###end p 30
###begin p 31
###xml 0 65 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946; signaling in normal colonic epithelium and cancer cells. </bold>
###xml 65 73 62 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel A </bold>
###xml 776 780 752 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p15 </italic>
###xml 843 845 819 821 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 856 862 832 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAI-1 </italic>
###xml 951 959 927 935 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Panel B </bold>
###xml 1160 1171 1133 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 1382 1393 1352 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGF&#946;RII </italic>
###xml 1691 1695 1652 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p15 </italic>
###xml 1699 1705 1660 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAI-1 </italic>
TGFbeta signaling in normal colonic epithelium and cancer cells. Panel A describes the functional pathway of TGFbeta signaling in normal colonic epithelial cells. TGFbeta ligand binding with TGFbetaRII recruits TGFbetaRI into a tetrameric receptor complex resulting in transphosphorylation and activation of TGFbetaRI. After phosphorylation, the TGFbetaRI becomes an active kinase which phosphorylates Smad 2 and Smad3. SARA (Smad Anchor for Receptor Activation), a scaffolding protein facilitates interaction between Smad2, Smad3 and TGFbetaRI. Phosphorylated Smad2 and Smad3 allow the formation of homo- and heterodimerization complex, including Smad4. The Smad complex then translocates into nucleus, binds with DNA, and stimulates the expression of target genes including p15 (inhibitor of cell cycle kinase that controls cell cycle into G1 phase) and PAI-1 (inhibitor of protease 1 that degrades extracellular matrix proteins during metastasis). Panel B shows the abnormal pathway of TGFbeta signaling in colon cancer cells. Many colon cancer cells with microsatellite instability (MSI) due to defective mismatch repair (MMR) activity induce mutations in TGFbetaRII gene. Often, these are frameshift mutations that insert or delete one or two adenine bases located within a 10 base-pair polyadenine repeat region (base-pairs 709-718, codons 125-128; referred to as BAT-RII) of TGFbetaRII gene. These mutations encode TGFbetaRII proteins truncated between 129 and 161 amino acids of the cytoplasmic domain which causes functional inactivation of these proteins. Thus, the loss of TGFbeta signaling may abolish cell cycle control and induce metastasis of colon cancer cells by inhibiting p15 and PAI-1 genes expression, respectively.
###end p 31
###begin title 32
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFIIR </italic>
Mutations in IGFIIR gene product augments TGFbeta1 signaling in MSI cells
###end title 32
###begin p 33
###xml 191 194 191 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B101">101</xref>
###xml 195 198 195 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B102">102</xref>
###xml 342 345 339 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B103">103</xref>
###xml 646 649 640 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B104">104</xref>
###xml 656 663 650 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGFIIR </italic>
###xml 748 750 742 744 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8 </sub>
###xml 891 893 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
Insulin like growth factor II receptor (IGFIIR) plays a critical role in cell growth, survival and differentiation; however, once mutated, these receptors play a major role in tumorigenesis [101,102]. The IGFIIR/mannose-6 phosphate receptor (M6PR) interacts with both IGF-II and latent TGFbeta1 ligands and acts as a tumor growth suppressor [103]. The IGFIIR performs its growth suppressive function by two different mechanisms. In one case, it binds and stimulates the plasmin-mediated cleavage and activation of the latent TGFbeta1; in the second case, it participates in the internalization and degradation of its own ligand IGFII, a mitogen [104]. The IGFIIR gene harbors several microsatellites within its coding region; one of them is poly(G)8 repeat which is often mutated with 1- or 2-base pair deletions or insertions. These mutations produce frameshifts and premature stop codons [89]. Thus, the loss of IGFIIR function due to mutations in MSI cells may enhance cell proliferation due to accumulation and activation of IGFII and down-regulation of TGFbeta1.
###end p 33
###begin title 34
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
Mutations in PTEN gene causes activation of PI3K and Akt oncogenic signals in MSI cells
###end title 34
###begin p 35
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMAC</italic>
###xml 153 158 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEP-1</italic>
###xml 369 374 366 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 558 566 555 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Proteus </italic>
###xml 580 587 577 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Proteus</italic>
###xml 604 607 601 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B105">105</xref>
###xml 608 611 605 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B110">110</xref>
###xml 719 722 716 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B109">109</xref>
###xml 723 726 720 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B111">111</xref>
###xml 827 829 824 826 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6 </sub>
###xml 897 900 894 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B112">112</xref>
###xml 1164 1167 1161 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B113">113</xref>
###xml 1168 1171 1165 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B114">114</xref>
###xml 1373 1376 1370 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B115">115</xref>
###xml 1692 1697 1689 1694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN </italic>
###xml 1804 1808 1801 1805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 1808 1812 1805 1809 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 1880 1884 1877 1881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTEN</italic>
###xml 1884 1888 1881 1885 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/+ </sup>
###xml 2031 2034 2028 2031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B116">116</xref>
###xml 1721 1726 <span type="species:ncbi:9606">human</span>
###xml 1781 1786 <span type="species:ncbi:10090">mouse</span>
###xml 1828 1832 <span type="species:ncbi:10090">mice</span>
###xml 1888 1892 <span type="species:ncbi:10090">mice</span>
The PTEN tumor suppressor gene, also known as mutated in multiple advanced cancers (MMAC) or TGFbeta-regulated and epithelial cell-enriched phosphatase (TEP-1), is located on chromosome 10q23. A homologous deletion of this gene has been found in sporadic glioma, endometrial, melanoma, prostate, renal, meningioma and small cell lung carcinomas. Germ-line mutations in PTEN gene is linked with autosomal dominant inherited cancer syndromes such as Cowden's disease, Lhermitte-Duclos disease, and Bannqayan-Zonana syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus syndrome, and Proteus-like syndromes [105-110]. In endometrial and colorectal cancers, the mutations in PTEN gene occur in MMR function-deficient cells [109,111]. The coding region of the PTEN gene contains several microsallites, among which a repeat of poly(A)6 tract in exon 7 and 8 are most susceptible to frameshift mutations [112]. PTEN is involved in cell cycle arrest and apoptosis through negatively regulating the survival signaling mediated by phosphatidylinositol 3-phsophate (PIP3) kinase (PI3K) and its down-stream target, a serine/threonine kinase Akt (also called protein kinase B) [113,114]. Once cells receive signals through growth factors, hormones, or extracellular matrix components, the Akt is recruited by PIP3 to the plasma membrane, where it is phosphorylated at the Ser473/Thr308 [115]. The phosphorylated Akt is involved in cell survival, proliferation and migration. Thus, the loss in PTEN causes elevation of intracellular PIP3 level that stimulates Akt kianse activity. The active Akt leads to tumorigenesis due to loss of proliferative and apoptotic controls of cell growth. The genetic data of PTEN gene mutations found in human tumors were further supported by animal studies. In a mouse model study, the PTEN-/- homozygous null mice was found to be embryonic lethal; however, the PTEN-/+ mice developed neoplasm in various organs, including breast, prostate, endometrium, adrenal, lymphoid, skin, colon, thyroid, liver and thymus [116].
###end p 35
###begin title 36
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F4 </italic>
Mutations in E2F4 gene looses cell cycle control in MSI cells
###end title 36
###begin p 37
###xml 229 232 229 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B117">117</xref>
###xml 233 236 233 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B119">119</xref>
###xml 914 917 914 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B120">120</xref>
###xml 918 921 918 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B122">122</xref>
###xml 1203 1208 1203 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F4 </italic>
###xml 1291 1294 1291 1294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">13 </sub>
###xml 1493 1495 1493 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 1514 1519 1514 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E2F4 </italic>
###xml 1614 1615 1614 1615 <sub xmlns:xlink="http://www.w3.org/1999/xlink">o</sub>
###xml 1617 1619 1617 1619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The ability of pRb to regulate cell cycle progression is dependent upon its interaction with E2F/DP family of transcription factors which are required for the regulation of a large number of genes involved in cell proliferation [117-119]. There are at least six E2F proteins which can be categorized into distinct subgroups that act in direct opposition to one another to promote either cellular proliferation or cell-cycle exit and terminal differentiation. The E2F1, E2F2 and E2F3 proteins can be grouped in one subgroup since they all directly interact with pRb and are strong transcriptional activators. The E2F4 and E2F5 proteins are comparatively less strong transcriptional activators or sometimes act as repressors by recruiting the pocket proteins (BOX 2) and their associated histone-modifying enzymes. The E2F6 acts as a repressor through its interaction with Bmi1-containing Polycom group of proteins [120-122]. The E2F4 and E2F5 transcription factors are also different than their other family members in that these factors lack the cyclin A binding domain. Furthermore, there is another critical feature in the E2F4 gene which is distinct from its family members. The coding region of the E2F4 gene contains a longer spacer segment of a repeated sequence of trinucleotide (CAG)13 that encodes 13 consecutive serine residues; this region is highly vulnerable to frameshift mutations in MSI cells. In MMR defective colorectal tumors, mutations in the E2F4 gene have been observed [91]. Thus, defective E2F4 gene expression in MSI colon cancer cells can possibly promote cell cycle progression through Go/G1 transition.
###end p 37
###begin title 38
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax </italic>
Mutations in pro-apoptotic gene Bax in MSI cells
###end title 38
###begin p 39
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax </italic>
###xml 201 202 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink">8</sub>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
###xml 208 211 208 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B123">123</xref>
###xml 748 751 748 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B124">124</xref>
Approximately 50% of the tumors with MSI are found with mutations in the Bax gene. These mutations produce frameshift mutations within a coding region of eight nucleotide stretch of guanine residues (G8) [93,123]. Bax heterodimerizes with anti-apoptotic protein Bcl2 and induces apoptosis. In the presence of apoptotic signals, BH3 domain proteins tBid are activated and bound with Bax. The interaction of tBid with Bax brings conformational changes in Bax, and this promotes its translocation to the mitochondria. Bax oligomerizes and inserts into the outer mitochondrial membrane where it forms channels to release cytochrome c (Cyt c) into the cytoplasm. The released Cyt c forms a complex called apoptosome with Apaf-1, dATP and pro-caspase 9 [124]. The apoptosome recruits and processes pro-caspase 9 to form a holoenzyme complex, which in turn recruits and activates the effector caspases leading to apoptosis. Thus, the expression of mutated Bax protein may fail to release Cyt c and increase the Bax-Bcl2 ratio resulting in the escape from apoptosis and inducing initiation of colorectal carcinogenesis.
###end p 39
###begin title 40
###xml 20 23 20 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLM</italic>
Mutations in Bloom (BLM) syndrome helicase gene in MSI cells
###end title 40
###begin p 41
###xml 139 142 139 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B125">125</xref>
###xml 143 146 143 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B126">126</xref>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLM </italic>
###xml 733 736 733 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B127">127</xref>
###xml 737 740 737 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B128">128</xref>
###xml 990 993 990 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B129">129</xref>
###xml 1157 1160 1157 1160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B130">130</xref>
###xml 1192 1196 1192 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLM </italic>
###xml 1491 1494 1491 1494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B131">131</xref>
###xml 1875 1879 1875 1879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLM </italic>
###xml 1885 1887 1885 1887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
###xml 1888 1891 1888 1891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B132">132</xref>
###xml 1892 1895 1892 1895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B133">133</xref>
###xml 1959 1963 1959 1963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLM </italic>
###xml 2047 2051 2047 2051 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BLM </italic>
###xml 2096 2107 2096 2107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax, hMSH6 </italic>
###xml 2114 2120 2114 2120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMSH3 </italic>
###xml 1550 1558 <span type="species:ncbi:9606">patients</span>
Bloom syndrome (BS) is a rare autosomal recessive inherited cancer predisposition caused by inactivation of the RecQ family helicase, BLM [125,126]. The genetic disorder of the BLM gene is characterized by growth deficiency, impaired fertility, proportional dwarfism, sun-sensitive telangiectatic erythema, immunodeficiency and premature ageing. The function of the BLM helicase is implicated in reinitiating DNA replication forks that are blocked at lesions, thereby promoting chromosome stability, which is characterized by elevated sister chromatid exchanges (SCEs), as well as chromosomal breaks, deletions, and rearrangements. Also, BLM helicases perform essential roles in genetic recombination, transcription, and DNA repair [127,128]. In all the above systems, the helicase activities derive energy from hydrolysis of ATP. BLM is a part of BRCA1-associated genome surveillance complex (BASC) which includes MSH2, MHS6, MLH1, ATM, RAD50-MRE11-NBS1 complex, and replication factor C [129]. BLM also interacts with heterotrimeric, single-stranded DNA binding protein, replication protein A (RPA), which after binding, stimulates BLM helicase activity [130]. The genetic structure of the BLM gene coding region contains 4,437 base-pairs and encodes 1,417 amino acids. The BLM helicase has different motifs which are assigned to different activities. Motifs Ia, III and V contain residues that establish direct contact with ssDNA and motifs I, II-IV and VI form a pocket for binding ATP [131]. It has been observed that many point mutations in BS patients are confined to these conserved helicase motifs, thus disrupting its ATPase and helicase activity. DNA sequencing from the sporadic gastrointestinal tumors showed abnormal bands caused by a deletion of one adenine residue in the poly-adenine tract (reduction from nine to eight adenines) in the coding region of the BLM gene [95,132,133]. Since these tumors had defective MMR genes, mutations in the BLM gene is directly linked with MSI and chromosomal instability pathways. Mutations in BLM gene has been associated with frameshifts in Bax, hMSH6 and/or hMSH3 with multiple unstable mono- and trinucleotide repeats located in coding regions that were significantly higher than that observed in microsatellite mutator phenotype positive tumors without BLM frameshifts. From these studies, it has been suggested that BLM loss of function by MSI in sporadic gastrointestinal tumors might be an intermediate mutational event, which may increase the instability of a pre-existent unstable genotype.
###end p 41
###begin title 42
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tcf-4</italic>
Mutations in T-cell factor 4 (Tcf-4) gene in MSI cells
###end title 42
###begin p 43
###xml 10 11 10 11 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 502 504 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 722 725 704 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B134">134</xref>
###xml 945 949 924 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 953 959 932 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTTNB </italic>
###xml 1067 1073 1043 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tcf-4 </italic>
###xml 1103 1106 1079 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B135">135</xref>
###xml 1107 1110 1083 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B137">137</xref>
###xml 1149 1151 1125 1127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">9 </sub>
###xml 1180 1186 1156 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tcf-4 </italic>
###xml 1519 1521 1495 1497 <sub xmlns:xlink="http://www.w3.org/1999/xlink">9 </sub>
###xml 1535 1541 1511 1517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tcf-4 </italic>
###xml 1705 1708 1681 1684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B138">138</xref>
###xml 1709 1712 1685 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B140">140</xref>
###xml 1823 1826 1799 1802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B141">141</xref>
###xml 2056 2059 2029 2032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B142">142</xref>
###xml 2115 2121 2088 2094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tcf-4 </italic>
###xml 2260 2263 2233 2236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B140">140</xref>
In Figure 3, disruption of the APC/beta-catenin pathway is shown as a critical step in the development of colorectal and other cancers. The oncogenic beta-catenin translocates into nucleus, heterodimerizes with the Tcf/Lef family of proteins, and transcribes target genes. The transcription factor Tcf-4 is one of the Tcf-family proteins, which forms a transcription complex with beta-catenin and plays an important role in maintenance of normal epithelial growth and development of colorectal tumors [35]. The Tcf-4/beta-catenin transcriptional activity is inhibited by protein Icat (inhibitor of beta-catenin and Tcf-4), which blocks the interaction between beta-catenin and Tcf-4 and thereby antagonizes Wnt-signaling [134]. Since the APC/Tcf-Lef/beta-catenin pathway plays an important role in colorectal cancer development, mutational analysis of these genes is critical to evaluate their functions. The mutations and their consequences in APC and CTTNB (beta-catenin) genes are discussed earlier, which are characteristics of CIN. However, the mutations in the Tcf-4 gene were found in MSI cells [135-137]. In MSI cells, an error-prone poly(A)9 monorepeat in exon 17 of the Tcf-4 gene frequently shows frameshift mutations by deletion of one nucleotide producing a short and medium isoform of the Tcf-4 protein. The transactivating properties of these shorter Tcf-4 isoforms in the development of colorectal cancers are still not clear. Recently, it has been suggested that the frameshift mutations in the poly(A)9 region of the Tcf-4 gene may in fact produce a gain in function of the shorter Tcf-4 isoform due to loss of binding sites of the transcriptional suppressor molecules, CtBP or Grg/TLE [138-140]. These mutated Tcf-4 proteins also lose the binding of chromatin remodeling complexes containing Osa/Brahma [141]. Thus, based on these studies, it is expected that mutated Tcf-4 protein may acquire increased transcriptional activity by increased binding affinity for beta-catenin or by facilitating the structural organization of chromatin [142]. Finally, it has been suggested that mutations in the Tcf-4 gene may not have significant effect and thus it may contribute marginally to the colorectal carcinogenesis or act as passenger mutations [140].
###end p 43
###begin title 44
Conclusions
###end title 44
###begin p 45
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 497 501 497 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 565 568 565 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras</italic>
###xml 570 573 570 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCC</italic>
###xml 579 582 579 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
Development of colorectal cancer is a complex and multi-step process in which several gene defects coordinate with each other in genotypic and phenotypic outcome. Mutations in many tumor suppressor and proto-oncogenes in the development of sporadic and hereditary colorectal cancers are well established; however, their precise role in this process is still not clear. For example, it is now established that mutations in the APC gene may be necessary for the early onset of FAP. Mutations in the APC gene perhaps set a stage for mutations in other genes such as K-ras, DCC, and p53. However, the mechanism(s) by which APC gene mutations may contribute to the accumulation of mutations in these genes that are associated with the colon cancer progression remains unclear. Mutations in the MMR genes can be linked to increased rate of mutations; however, studies indicate that MMR negative cells develop resistance to apoptosis rather than accumulation of mutations. Thus, MMR gene mutations and its role in MSI and apoptosis need further investigation in context with apoptosis and cell cycle-related genes. These studies will provide a better understanding of colorectal cancer development and its intervention by genetic or chemotherapeutic means.
###end p 45
###begin title 46
Authors' contributions
###end title 46
###begin p 47
SN drafted the paper. DR provided suggestions for its finalization. Both authors read and approved the final version of the manuscript.
###end p 47
###begin title 48
Acknowledgements
###end title 48
###begin p 49
The work in our laboratory on APC is currently supported to S. N. by NCI-NIH (CA-097031, CA-100247) and Flight Attendants Medical Research Institute, Miami, FL. I thank the members of my laboratory for their comments and to Nirupama Gupta and Mary Wall for their critical reading of this manuscript. I apologize to those colleagues whose work was not cited; instead, many of them have been accommodated in referenced review articles.
###end p 49
###begin article-title 50
The evolution of cancer of the colon and rectum
###end article-title 50
###begin article-title 51
A genetic model for colorectal tumorigenesis
###end article-title 51
###begin article-title 52
The somatic evolution of cancer. The Harveian Oration of 1996
###end article-title 52
###begin article-title 53
Genetic pathways in colorectal and other cancers
###end article-title 53
###begin article-title 54
Mutations in APC, Kirsten-ras, and p53 - alternative genetic pathways to colorectal cancer
###end article-title 54
###begin article-title 55
Biology of the adenomatous polyposis coli tumor suppressor
###end article-title 55
###begin article-title 56
The ABC of APC
###end article-title 56
###begin article-title 57
The molecular basis of Turcot's syndrome
###end article-title 57
###begin article-title 58
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Loss of heterozygosity affecting the APC and MCC genetic loci in patients with primary breast carcinomas
###end article-title 58
###begin article-title 59
Somatic mutations of the APC gene in primary breast cancers
###end article-title 59
###begin article-title 60
LOH at the APC/MCC gene (5Q21) is frequent in early stages of non-small cell lung cancer
###end article-title 60
###begin article-title 61
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
Decreased expression of the adenomatous polyposis coli (Apc) and mutated in colorectal cancer (Mcc) genes in mouse lung neoplasia
###end article-title 61
###begin article-title 62
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 78 80 78 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase
###end article-title 62
###begin article-title 63
###xml 73 76 <span type="species:ncbi:10116">rat</span>
Up-regulation of the APC gene product during neuronal differentiation of rat pheochromocytoma PC12 cells
###end article-title 63
###begin article-title 64
Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34
###end article-title 64
###begin article-title 65
beta-Catenin Regulation during the Cell Cycle: Implications in G2/M and Apoptosis
###end article-title 65
###begin article-title 66
Protein synthesis and transcriptional inhibitors control N-methyl-N'-nitro-N-nitrosoguanidine-induced levels of APC mRNA in a p53-dependent manner
###end article-title 66
###begin article-title 67
p53-dependent Transcriptional regulation of the APC promoter in colon cancer cells treated with DNA-alkylating agents
###end article-title 67
###begin article-title 68
Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53
###end article-title 68
###begin article-title 69
###xml 51 56 <span type="species:ncbi:10090">mouse</span>
Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers
###end article-title 69
###begin article-title 70
###xml 142 150 <span type="species:ncbi:9606">patients</span>
Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients
###end article-title 70
###begin article-title 71
APC genotype, polyp number, and surgical options in familial adenomatous polyposis
###end article-title 71
###begin article-title 72
APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis
###end article-title 72
###begin article-title 73
Wnt signaling and cancer
###end article-title 73
###begin article-title 74
The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germ-line mutation: a new facet to Knudson's 'two-hit' hypothesis
###end article-title 74
###begin article-title 75
###xml 12 17 <span type="species:ncbi:10090">mouse</span>
Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development
###end article-title 75
###begin article-title 76
Forced expression of the tumor suppressor adenomatous polyposis coli protein induces disordered cell migration in the intestinal epithelium
###end article-title 76
###begin article-title 77
Nuclear localizations of the adenomatous polyposis coli protein
###end article-title 77
###begin article-title 78
Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover
###end article-title 78
###begin article-title 79
The APC tumour suppressor has a nuclear export function
###end article-title 79
###begin article-title 80
Role of BAX in the apoptotic response to anticancer agents
###end article-title 80
###begin article-title 81
Adenomatous polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and cytoplasm
###end article-title 81
###begin article-title 82
Phosphorylation near nuclear localization signal regulates nuclear import of adenomatous polyposis coli protein
###end article-title 82
###begin article-title 83
The ins and outs of APC and beta-catenin nuclear transport
###end article-title 83
###begin article-title 84
###xml 76 80 73 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma
###end article-title 84
###begin article-title 85
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC
###end article-title 85
###begin article-title 86
Stabilization of beta-catenin by genetic defects in melanoma cell lines
###end article-title 86
###begin article-title 87
Wnt signaling: a common theme in animal development
###end article-title 87
###begin article-title 88
Signal transduction through beta-catenin and specification of cell fate during embryogenesis
###end article-title 88
###begin article-title 89
Signal transduction by the Wnt family of ligands
###end article-title 89
###begin article-title 90
beta-catenin is a target for the ubiquitin-proteasome pathway
###end article-title 90
###begin article-title 91
Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin
###end article-title 91
###begin article-title 92
Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta
###end article-title 92
###begin article-title 93
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin
###end article-title 93
###begin article-title 94
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin
###end article-title 94
###begin article-title 95
Association of the APC gene product with beta-catenin
###end article-title 95
###begin article-title 96
Association of the APC tumor suppressor protein with catenins
###end article-title 96
###begin article-title 97
Identification of c-MYC as a target of the APC pathway
###end article-title 97
###begin article-title 98
beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
###end article-title 98
###begin article-title 99
The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors
###end article-title 99
###begin article-title 100
###xml 81 86 <span type="species:ncbi:9606">human</span>
Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas
###end article-title 100
###begin article-title 101
Identification of CDK4 as a target of c-MYC
###end article-title 101
###begin article-title 102
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
###end article-title 102
###begin article-title 103
The adenomatous polyposis coli protein: in the limelight out at the edge
###end article-title 103
###begin article-title 104
###xml 54 64 <span type="species:ncbi:7227">Drosophila</span>
Adherens junctions inhibit asymmetric division in the Drosophila epithelium
###end article-title 104
###begin article-title 105
###xml 42 52 <span type="species:ncbi:7227">Drosophila</span>
Actin-dependent membrane association of a Drosophila epithelial APC protein and its effect on junctional Armadillo
###end article-title 105
###begin article-title 106
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 43 53 <span type="species:ncbi:7227">Drosophila</span>
Binding of APC to the human homolog of the Drosophila discs large tumor suppressor protein
###end article-title 106
###begin article-title 107
The APC-hDLG complex negatively regulates cell cycle progression from the G0/G1 to S phase
###end article-title 107
###begin article-title 108
Regulation of cadherin adhesive activity
###end article-title 108
###begin article-title 109
Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer
###end article-title 109
###begin article-title 110
###xml 50 55 <span type="species:ncbi:9606">human</span>
E-cadherin-catenin cell-cell adhesion complex and human cancer
###end article-title 110
###begin article-title 111
The protein tyrosine phosphatase Pez is a major phosphatase of adherens junctions and dephosphorylates beta-catenin
###end article-title 111
###begin article-title 112
Cadherins and catenins in development
###end article-title 112
###begin article-title 113
Role of the E-cadherin-catenin complex in modulating cell-cell and cell-matrix adhesive properties of invasive colon carcinoma cells
###end article-title 113
###begin article-title 114
Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration
###end article-title 114
###begin article-title 115
###xml 36 41 <span type="species:ncbi:9606">human</span>
Cadherin and catenin alterations in human cancer
###end article-title 115
###begin article-title 116
Inward growth of colonic adenomatous polyps
###end article-title 116
###begin article-title 117
The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain
###end article-title 117
###begin article-title 118
APC, beta-catenin and hTcf-4; an unholy trinity in the genesis of colorectal cancer
###end article-title 118
###begin article-title 119
Glycogen synthase kinase 3beta phosphorylation of microtubule-associated protein 1B regulates the stability of microtubules in growth cones
###end article-title 119
###begin article-title 120
Phosphorylated tau can promote tubulin assembly
###end article-title 120
###begin article-title 121
Asef, a link between the tumor suppressor APC and G-protein signaling
###end article-title 121
###begin article-title 122
Mutated APC and ASEF are involved in the migration of colorectal tumour cells
###end article-title 122
###begin article-title 123
Mutations in the APC tumour suppressor gene cause chromosomal instability
###end article-title 123
###begin article-title 124
A role for the Adenomatous Polyposis Coli protein in chromosome segregation
###end article-title 124
###begin article-title 125
###xml 49 54 <span type="species:ncbi:9606">human</span>
Securin is required for chromosomal stability in human cells
###end article-title 125
###begin article-title 126
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 71 77 <span type="species:ncbi:9606">humans</span>
Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
###end article-title 126
###begin article-title 127
Mammalian DNA mismatch repair
###end article-title 127
###begin article-title 128
Genetic susceptibility to non-polyposis colorectal cancer
###end article-title 128
###begin article-title 129
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Mutational germ-line analysis of hMSH2 and hMLH1 genes in early onset colorectal cancer patients
###end article-title 129
###begin article-title 130
hMutSbeta, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA
###end article-title 130
###begin article-title 131
Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
###end article-title 131
###begin article-title 132
Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression
###end article-title 132
###begin article-title 133
###xml 88 93 <span type="species:ncbi:9606">human</span>
Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
###end article-title 133
###begin article-title 134
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
###end article-title 134
###begin article-title 135
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
###end article-title 135
###begin article-title 136
Mutation of MSH3 in endometrial cancer and evidence for its functional role in heteroduplex repair
###end article-title 136
###begin article-title 137
Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours
###end article-title 137
###begin article-title 138
###xml 74 79 <span type="species:ncbi:9606">human</span>
Mutation of hMSH3 and hMSH6 mismatch repair genes in genetically unstable human colorectal and gastric carcinomas
###end article-title 138
###begin article-title 139
Mutations of E2F-4 trinucleotide repeats in colorectal cancer with microsatellite instability
###end article-title 139
###begin article-title 140
The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum
###end article-title 140
###begin article-title 141
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
###end article-title 141
###begin article-title 142
###xml 58 63 <span type="species:ncbi:9606">human</span>
Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors
###end article-title 142
###begin article-title 143
The coding region of the Bloom syndrome BLM gene and of the CBL proto-oncogene is mutated in genetically unstable sporadic gastrointestinal tumors
###end article-title 143
###begin article-title 144
A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms
###end article-title 144
###begin article-title 145
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
###end article-title 145
###begin article-title 146
Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer
###end article-title 146
###begin article-title 147
Analysis of TGF-beta-mediated synthesis of extracellular matrix components
###end article-title 147
###begin article-title 148
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest
###end article-title 148
###begin article-title 149
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes
###end article-title 149
###begin article-title 150
Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors
###end article-title 150
###begin article-title 151
The insulin-like growth factor system and cancer
###end article-title 151
###begin article-title 152
Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells
###end article-title 152
###begin article-title 153
Deficient transforming growth factor-beta1 activation and excessive insulin-like growth factor II (IGFII) expression in IGFII receptor-mutant tumors
###end article-title 153
###begin article-title 154
Germ-line mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
###end article-title 154
###begin article-title 155
Germ-line mutations in PTEN are present in Bannayan-Zonana syndrome
###end article-title 155
###begin article-title 156
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
###end article-title 156
###begin article-title 157
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome
###end article-title 157
###begin article-title 158
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers
###end article-title 158
###begin article-title 159
PTEN mutations and proteus syndrome
###end article-title 159
###begin article-title 160
PTEN gene mutations in colorectal cancers displaying microsatellite instability
###end article-title 160
###begin article-title 161
Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis
###end article-title 161
###begin article-title 162
PTEN: a tumour suppressor that functions as a phospholipid phosphatase
###end article-title 162
###begin article-title 163
PTEN: The down side of PI 3-kinase signalling
###end article-title 163
###begin article-title 164
###xml 47 52 <span type="species:ncbi:9606">human</span>
The protein kinase B/Akt signalling pathway in human malignancy
###end article-title 164
###begin article-title 165
PTEN signaling pathways in melanoma
###end article-title 165
###begin article-title 166
Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner
###end article-title 166
###begin article-title 167
E2F: a link between the Rb tumor suppressor protein and viral oncoproteins
###end article-title 167
###begin article-title 168
Transcriptional inhibition by the retinoblastoma protein
###end article-title 168
###begin article-title 169
The E2F6 transcription factor is a component of the mammalian Bmi1-containing polycomb complex
###end article-title 169
###begin article-title 170
Sibling rivalry in the E2F family
###end article-title 170
###begin article-title 171
A revised picture of the E2F transcriptional network and RB function
###end article-title 171
###begin article-title 172
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
###end article-title 172
###begin article-title 173
The Apaf-1 apoptosome: a large caspase-activating complex
###end article-title 173
###begin article-title 174
###xml 40 45 <span type="species:ncbi:9606">human</span>
DNA helicases, genomic instability, and human genetic disease
###end article-title 174
###begin article-title 175
###xml 31 36 <span type="species:ncbi:9606">human</span>
Recombinational DNA repair and human disease
###end article-title 175
###begin article-title 176
Mechanisms of helicase-catalyzed DNA unwinding
###end article-title 176
###begin article-title 177
Interactions of DNA helicases with damaged DNA: possible biological consequences
###end article-title 177
###begin article-title 178
DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders
###end article-title 178
###begin article-title 179
Replication protein A physically interacts with the Bloom's syndrome protein and stimulates its helicase activity
###end article-title 179
###begin article-title 180
Structural basis of Bloom syndrome (BS) causing mutations in the BLM helicase domain
###end article-title 180
###begin article-title 181
Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes
###end article-title 181
###begin article-title 182
Somatic frameshift mutations in the Bloom syndrome BLM gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype
###end article-title 182
###begin article-title 183
Inhibition of Wnt signaling by ICAT, a novel beta-catenin-interacting protein
###end article-title 183
###begin article-title 184
Frequent frameshift mutations of the TCF-4 gene in colorectal cancers with microsatellite instability
###end article-title 184
###begin article-title 185
Frequent alterations of the beta-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability
###end article-title 185
###begin article-title 186
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Genetic alterations in the human Tcf-4 gene in Japanese patients with sporadic gastrointestinal cancers with microsatellite instability
###end article-title 186
###begin article-title 187
TCF transcription factors: molecular switches in carcinogenesis
###end article-title 187
###begin article-title 188
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human T-cell transcription factor-4 gene: structure, extensive characterization of alternative splicings, and mutational analysis in colorectal cancer cell lines
###end article-title 188
###begin article-title 189
###xml 57 62 <span type="species:ncbi:9606">human</span>
T-cell factor-4 frameshift mutations occur frequently in human microsatellite instability-high colorectal carcinomas but do not contribute to carcinogenesis
###end article-title 189
###begin article-title 190
Osa-containing Brahma chromatin remodeling complexes are required for the repression of wingless target genes
###end article-title 190
###begin article-title 191
Regulation of LEF-1/TCF transcription factors by Wnt and other signals
###end article-title 191

